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Objectives This study aimed to evaluate the effect of cardiac resynchronization therapy with a defibrillator (CRT-D) on the
risks of first and recurrent ventricular tachyarrhythmic events (VTEs) in the MADIT-CRT.
Background Reverse remodeling associated with CRT-D therapy was suggested to reduce arrhythmic risk. However, the effect
of the device on the risk of recurrent VTEs among patients who experience a first arrhythmic event has not been
investigated.
Methods The CRT-D versus defibrillator-only risks for first and subsequent fast VTEs (180 beats/min) were assessed by
Cox proportional hazards and Andersen-Gill proportional intensity regression modeling, respectively, in efficacy
analyses recognizing active device-type during follow-up.
Results Multivariate analysis showed that CRT-D was associated with a significant 29% (p  0.003) reduction in the risk
of a first VTE, with a pronounced effect among patients with left bundle branch block (LBBB) (hazard ratio [HR]:
0.58; p  0.001) and no significant effect among non-LBBB patients (HR: 1.05; p  0.82, p for the difference 
0.02). Patients with LBBB who experienced a first VTE had no change in the risk of subsequent VTEs with CRT-D
(HR: 0.98; p  0.85). In contrast, the risk of recurrent VTEs with CRT-D was significantly increased among non-
LBBB patients (HR: 3.62; p  0.002, p for the difference  0.009). Recurrent VTEs increased the risk of subse-
quent heart failure or death.
Conclusions In MADIT-CRT, active treatment with CRT-D was associated with a significant reduction in the risk of life-threatening VTEs.
However, our findings suggest that CRT-D does not reduce the risk of subsequent VTEs in patients who experience a first
arrhythmic event and may increase subsequent arrhythmic risk in non-LBBB patients. (Multicenter Automatic Defibrillator
Implantation With Cardiac Resynchronization Therapy [MADIT-CRT]; NCT00180271) (J Am Coll Cardiol 2012;60:
1809–16) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.05.057Patients with congestive heart failure are at an increased risk
of life-threatening ventricular arrhythmias due to ischemia
or myocardial substrate changes (1). The incidence of
sudden cardiac death approaches 20% in those with ejection
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accepted May 28, 2012.fractions 30% (1). Evidence-based consensus guidelines
recommend treatment with implantable cardioverter-
defibrillators (ICDs) in patients with New York Heart
Association (NYHA) functional class I/III symptoms and
reduced ejection fraction due to a previous myocardial
infarction to reduce mortality (2). Similar results, albeit
less robust, have also been reported in patients with heart
failure of nonischemic etiology and resulted in guideline
inclusions (3–5).
The MADIT-CRT (Multicenter Automatic Defibrilla-
tor Implantation Trial With Cardiac Resynchronization
Therapy) showed that cardiac resynchronization therapy
with a defibrillator (CRT-D) is associated with a significant
reduction in the risk of heart failure hospitalizations or
all-cause mortality in patients with prolonged QRS duration
and mild heart failure symptoms (NYHA class I or II) of
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ogies (6). These results were sub-
sequently confirmed in a popula-
tion of patients with mild to
moderate heart failure (NYHA
class II or III) (7). The ventricu-
lar conduction pattern has been
shown to be an important pa-
rameter to predict response to
cardiac resynchronization ther-
apy (CRT) because patients with
left bundle branch block (LBBB)
appear to derive greater benefit
from CRT than those with other
conduction abnormalities in
terms of time to a first and recur-
rent heart failure events (8,9). In
this MADIT-CRT substudy, we
seek to: 1) elucidate the impact
of CRT on the occurrence of first and recurrent ventricular
tachyarrhythmic events (VTEs) in mildly symptomatic heart
failure patients; 2) relate recurrent arrhythmic risk in this
population to QRS morphology; and 3) assess the prognos-
tic implications of first and recurrent VTEs.
Methods
Study population. The details of the MADIT-CRT have
been described; specifically, the trial investigated the effect
of CRT-D versus ICD alone in patients with early heart
failure, either in NYHA class I or II due to ischemic
etiologies or NYHA class II due to nonischemic cardiomy-
opathy, reduced ejection fraction (30%), ventricular con-
duction delay as evidenced by QRS duration 130 ms (6).
This current substudy comprises all 1,820 MADIT-CRT
patients.
Data acquisition and follow-up. The MADIT-CRT be-
gan on December 22, 2004, and ended by recommendation
of the data and safety monitoring board on June 22, 2009.
However, additional data collection on heart failure events,
mortality, and arrhythmia endpoints were collected through
December 31, 2009. Data regarding VTEs were collected
via device interrogation and evaluated by an independent
committee. Device crossovers were recorded during follow-
up. Thirty-seven percent of patients initially allocated to
ICD-only therapy crossed over to CRT-D, whereas only
8% of those initially allocated to CRT-D crossed over to
ICD-only therapy. Although devices were initially pro-
grammed in the same manner, individual physicians were
permitted to change the device settings. Further informa-
tion about the trial design and procedures was previously
reported (6,10).
Device programming and interrogation. Commercially
available transvenous devices (Boston Scientific, Natick,
Massachusetts) were used in the trial. Standard techniques
Abbreviations
and Acronyms
ATP  antitachycardia
pacing
CRT  cardiac
resynchronization therapy
CRT-D  cardiac
resynchronization therapy
with a defibrillator
HR  hazard ratio
ICD  implantable
cardioverter-defibrillator
LBBB  left bundle branch
block
NYHA  New York Heart
Association
VTE  ventricular
tachyarrhythmic eventwere used to implant the CRT-D and ICD-only devices.Device testing and programming were performed as
reported previously (10). Devices were programmed to
monitor  therapy, with a protocol recommendation to a
etting of the ventricular tachycardia zone at 180 beats/min,
nd the ventricular fibrillation zone at 250 beats/min.
ensitivity was programmed according to physician discre-
ion. Detection was 2.5 s for the ventricular tachycardia
one and 1.0 s for the ventricular fibrillation zone. The
rotocol recommended programming the ventricular tachy-
ardia zone first therapy to burst-type antitachycardia pac-
ng (ATP) with 8 pulses at 88% of the measured cycle
ength with a 10-ms decrement between bursts, then shock
herapy; second therapy should be shock at the defibrillation
hreshold plus at least 10 J (if possible). The remaining
herapies should be maximal energy shocks. The ICDs were
nterrogated quarterly, after which ICD shocks and disks
ere sent to the core laboratory for categorization and final
valuation of detected arrhythmias. An arrhythmia episode
as defined as any type of therapy that is rendered including
TP and shock. Only appropriate therapies delivered for
ast VTEs (180 beats/min) were considered in the present
tudy.
chocardiographic methods and outcome measures.
chocardiograms were obtained according to a study-
pecific protocol at baseline, which was before device im-
lantation (n  1,809), and at 1 year (n  626 in the ICD
group; n  752 in the CRT-D group). Paired echocardio-
grams from baseline and at 12 months with the device
turned on were available for 1,372 patients who composed
the present study population. Echocardiographic parameters
were measured in a core laboratory according to established
American Society of Echocardiography protocols (11). Left
ventricular volumes were measured by Simpson’s method of
discs in the apical 4- and 2-chamber views and averaged.
An echocardiographic response was defined as the per-
centage of reduction in left ventricular end-systolic volumes
between enrollment and 1 year (calculated as the difference
between 1-year cardiac volumes and baseline cardiac vol-
umes, divided by baseline cardiac volumes). CRT-D pa-
tients were categorized into 2 groups based on their echo-
cardiographic response: responders (defined as 25%
reduction [greater than the first quartile response] in left
ventricular end-systolic volume at 1 year post-implantation)
and nonresponders (defined as 25% reduction [greater
than the first quartile response] in left ventricular end-
systolic volume at 1 year post-implantation).
Study design and endpoints. The primary outcome of this
study was the occurrence of fast VTEs, herein defined as
appropriate ICD therapy delivered for ventricular tachycar-
dia/fibrillation with ventricular rates 180 beats/min. De-
vice therapies included in the fast VTE endpoint comprised
both ATP and shocks, with a detection threshold as defined
above. All therapies were adjudicated by an independent
committee that was blinded to treatment allocation. This
rate was selected as nearly all devices were programmed to
detect such arrhythmias. Only the first recorded VTE for
n
o
a
G
a
w
t
d
t
a
f
u
e
p
d
u
i
t
e
f
w
e
f
w
t
d
1811JACC Vol. 60, No. 18, 2012 Ouellet et al.
October 30, 2012:1809–16 CRT-D and Recurrent Ventricular Tachyarrhythmiaseach patient in any 24-h period of follow-up was included to
reduce the effect of ventricular tachycardia storms on the
primary outcome. As previously reported, because the ben-
efit of CRT-D appears to be restricted to patients with
LBBB at baseline (8), we further stratified the treatment
effects by QRS morphology.
Statistical methods. FIRST AND SUBSEQUENT VTEs. Be-
cause the risk of VTEs increased after a first event, the risk
of subsequent VTEs was analyzed separately from the first
VTE endpoint. No distinctions were made among subse-
quent VTEs because there was little differential risk for
second, third, and more VTEs.
EFFICACY ANALYSES. As previously mentioned, a large
umber of patients who were initially randomized to ICD-
nly treatment group crossed over to the CRT-D arm after
first heart failure exacerbation during trial follow-up.
iven that many of the ventricular arrhythmias occurred
fter the first heart failure exacerbation, an efficacy analysis
as applied for the present study, recognizing active device
ype during follow-up. We used the daily records of active
evice type to conduct an analysis of the primary outcome.
COVARIATE-ADJUSTED ANALYSES OF RISK. Cox propor-
ional hazards modeling was used to perform multivariate
nalysis of time to first VTE as well as time to first heart
ailure event or death. In the models, the treatment arm was
sed as a time-dependent covariate (i.e., comparing risks of
Baseline Patient Characteristics by the NumbeTable 1 Baseline Patient Characteristics b
No
n 1,4
Characteristic, %
Randomized to CRT-D
Age 65 yrs
Female
Ischemic NYHA functional class I
Ischemic NYHA functional class II
NYHA class III 3 months before enrollment
1 HF event during follow-up
LBBB
Previous MI
QRS duration 150 ms
BUN 25 mg/dl
SCr 1.4 mg/dl
Baseline echocardiographic parameters, %†
LVEF 25%
LVEDV 240 ml/m2
Baseline medications, %
Amiodarone
Beta-blockers
All entries are percentages with the characteristics among those wh
the overall differences between the number of VTE groups. *The stat
using a chi-square test comparing 4 percentages. †All echocardiograp
indexed to body mass index.
BUN blood urea nitrogen; CRT-D cardiac resynchronization ther
left ventricular end-diastolic volume; LVEF  left ventricular ejection fractio
SCr  serum creatinine; VTE  ventricular tachyarrhythmic event.vents occurring while specific devices were active by incor-
orating data for each patient after crossover between
evices). Several baseline characteristics were identified
sing best subsets for inclusion in the multivariate models
ncluding age older than 65 years at enrollment, left ven-
ricular end-diastolic volume 240 ml/m2 at enrollment
(corresponding to the approximate median value), sex,
etiology of heart failure (ischemic or nonischemic), history
of myocardial infarction, and history of a ventricular tachy-
arrhythmia. In an additional analysis, the occurrence of
heart failure during follow-up was accounted for by includ-
ing this factor as a time-dependent covariate in the multi-
variate models. Anderson Gill proportional intensity regres-
sion was used to assess the same risk factors for recurrent
VTEs among patients who experienced a first VTE. All
models included a pre-specified treatment by QRS mor-
phology (LBBB or non-LBBB) interaction.
SURVIVAL CURVES. Survival curves were constructed for the
ntire study population and stratified by QRS morphology
rom the date of initial implant to the first VTE or death,
hichever occurred first. Among the patients who experi-
nced and survived a first VTE, survival curves were created
rom the time of the first VTE to a second VTE or death,
hichever occurred first, by the device type at the time of
he first VTE. Patients were censored at the time of any
evice change or explantation.
TEs During Follow-UpNumber of VTEs During Follow-Up
f VTEs Experienced During Follow-up
p Value*1 VTE 2 VTEs >3 VTEs
179 57 91
56 54 56 0.40
48 51 36 0.003
15 14 14 0.001
17 9 16 0.47
43 40 42 0.87
11 4 12 0.36
27 32 38 0.001
64 65 68 0.11
52 46 55 0.007
57 61 59 0.07
23 16 26 0.48
20 18 17 0.53
13 21 22 0.001
58 59 53 0.001
9 7 12 0.16
91 89 92 0.19
ienced the indicated number of VTEs during follow-up; p values are for
ignificance of differences between the 4 VTE subgroups was assessed
ameters are based on core laboratory data, and volumemeasures were
brillator; HF heart failure; LBBB left bundle branch block: LVEDVr of Vy the
No. o
VTE
93
61
55
27
14
40
10
15
72
42
66
25
22
10
44
7
94
o exper
istical s
hic par
apy defi
n; MI  myocardial infarction; NYHA  New York Heart Association;
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CRT-D and Recurrent Ventricular Tachyarrhythmias October 30, 2012:1809–16SOFTWARE. All hypothesis tests were 2 sided with a pre-
pecified significance level of 0.05. Statistical analysis was
erformed using SAS version 9.2 (SAS Institute Inc., Cary,
orth Carolina).
esults
total of 327 patients experienced at least 1 VTE with a
ate 180 beats/min, of whom 148 (45%) experienced at
east 1 subsequent VTE. The baseline characteristics of
tudy patients by the number of VTEs experienced during
ollow-up are shown in Table 1. Patients with fewer VTEs
ere more likely to be female, older than 65 years of age
t enrollment, and with a lower left-ventricular end-
iastolic volume on the baseline echocardiogram. In
ontrast, patients experiencing more VTEs were more
ikely to have a lower baseline ejection fraction, a previous
yocardial infarction, and a heart failure event during
ollow-up. Notably, the groups did not differ in the
roportion of patients with ischemic or nonischemic
ardiomyopathy, LBBB conduction pattern, blood urea
itrogen, creatinine, and treatment with standard medi-
ations for heart failure (Table 1).
ffect of CRT-D on the risk of first VTEs. In the total
tudy population, a Kaplan-Meier survival analysis showed
hat the cumulative probability for the occurrence of a first
TE or death was significantly lower among patients in the
RT-D group than in the ICD-only group (p  0.01)
Fig. 1A). When assessed by QRS morphology, treatment
ith CRT-D was shown to be associated with a signifi-
antly lower rate of a first VTE or death among patients
ith LBBB (p  0.001) (Fig. 1B), whereas among non-
BBB patients, event rates were nonsignificantly higher in
he CRT-D group (p  0.15) (Fig. 1C). Multivariate
nalysis consistently showed that in the total study popula-
ion, active treatment with CRT-D was associated with a
ignificant 29% (p  0.003) reduction in the risk of a first
TE compared with ICD-only therapy (Table 2). When
ssessed by QRS morphology, CRT-D was shown to be
ssociated with a 42% (p  0.001) reduction in the risk of a
rst VTE among patients with baseline LBBB, whereas
mong non-LBBB patients, the risk of a first VTE was not
ignificantly different between CRT-D and ICD-only pa-
ients (hazard ratio [HR]: 1.05, p  0.82, p for QRS
morphology-by-treatment interaction  0.016) (Table 2).
Effect of CRT-D on the risk of recurrent VTEs. Among
patients who experienced a first VTE, Kaplan-Meier sur-
vival analysis showed no statistically significant difference
between the treatment groups with regard to the occurrence
a second VTE or death (p  0.87) (Fig. 2A). Similarly,
when assessed by QRS morphology, the cumulative proba-
bility of a second VTE or death was not significantly
different between the 2 treatment groups among both
LBBB patients (p  0.42) (Fig. 2B) and non-LBBB
patients (p  0.086) (Fig. 2C).Consistent with the univariate findings, multivariate An-
derson Gill modeling (Table 2) showed that the benefit of
CRT-D for VTE reduction was not evident among those
Figure 1
Rate of First VTE or Death
by Treatment Arm in the Total Population
and Stratified by Baseline LBBB Status
Cumulative probability of the occurrence of a first ventricular tachyarrhythmic
event (180 beats/min) or death by treatment arm in the total study popula-
tion (A); study patients with left bundle branch block (B); and study patients
without left bundle branch block (C). Survival curves were limited to time from
implantation, with censoring at any device change or explantation. CRT-D 
cardiac resynchronization therapy with a defibrillator; ICD  implantable cardio-
verter-defibrillator; VF  ventricular fibrillation; VT  ventricular tachycardia.who experienced a first event. The treatment effect was
 ven
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October 30, 2012:1809–16 CRT-D and Recurrent Ventricular Tachyarrhythmiasagain significantly different between the different conduc-
tion disturbance groups. Among patients with LBBB, there
was a neutral treatment effect on the risk of recurrent VTEs
after a first event (HR: 0.98, p  0.95), whereas among
non-LBBB patients who experienced a first VTE, active
treatment with CRT-D was associated with 3-fold in-
crease in the risk of subsequent VTEs (HR: 3.62; p 
0.002, p for QRS morphology-by-treatment interaction 
0.009) (Table 2).
VTEs and the risk of subsequent heart failure or death.
The occurrence of a first VTE did not significantly increase
the risk of heart failure or death; however, second and third
VTEs were significantly associated with this risk (HR: 2.44;
p 0.010 and HR: 3.26; p 0.001, respectively [Table 3]).
There were no significant VTEs by QRS morphology
interactions, indicating a similar effect of cumulative VTEs
on the endpoint of heart failure or death between the QRS
morphology subgroups (not shown).
Notably, the effect of a first VTE on subsequent out-
comes was not significantly different between first events
associated with shock therapy versus those associated with
ATP (first shock vs. ATP risk of subsequent VTEs: HR:
0.86 [95% confidence interval: 0.62 to 1.19]; first shock
versus ATP risk of subsequent heart failure/death: HR: 0.86
[95% confidence interval: 0.52 to 1.43]).
Relation between change in cardiac volumes at 1 year and
the risk of subsequent VTEs. We carried out an addi-
tional exploratory analysis in an attempt to identify a
mechanistic link between the effect of CRT-D on the risk of
recurrent VTEs and its relation to QRS morphology.
Patients with non-LBBB conduction pattern were twice as
likely to have experienced a lack of response to CRT as
measured by echocardiographic parameters (48% in patients
with non-LBBB vs. 24% in patients with LBBB) (Fig. 3).
Multivariate analysis showed that among echocardiographic
responders at 1-year treatment with CRT-D was associated
with a significant 46% (p  0.001) reduction in the risk of
subsequent VTEs, whereas among echocardiographic nonre-
sponders, CRT-D was associated with a significant 45% (p 
Multivariate Analysis: Impact of Active Device Treatmenton the Occurrence of VTE in All Patients and by QRS Morphology*Table 2 Multivariate A alysis: Impact of Active Device Treatmon the Occurrence of VTE in All Patients and by QRS M
Endpoint†
All Patients
HR (95% CI) p Value HR (9
First VTE (CRT-D vs. ICD) 0.71 (0.57–0.89) 0.003 0.58 (0.
Subsequent VTEs (CRT-D vs. ICD) 1.58 (0.99–2.53) 0.05 0.98 (0.
*Efficacy analyses compare active CRT-D use relative to ICD use, using daily records; results for peri
in 1,820 patients (310 events) using Cox proportional hazards regression modeling, and the endpo
regression modeling. All findings are further adjusted for age 65 years and older at enrollment, le
of myocardial infarction, and history of a ventricular tachyarrhythmia before enrollment. For the su
results were obtained in the models that included the occurrence of time-dependent heart failur
identified once LBBB status was included in the model.
CI  confidence interval; HR  hazard ratio; ICD  implantable cardioverter-defibrillator; VTE0.001) increase in the risk of subsequent VTEs (Table 4).Discussion
To our knowledge, the present study is the first to assess the
effect of treatment with CRT-D on the risk of recurrent
VTEs. Our findings show that in the MADIT-CRT
population: 1) active treatment with CRT-D was associated
with a significant reduction in the risk of a VTE (180
beats/min); 2) the beneficial effects of CRT-D therapy on
the risk of a first VTE were related to a pronounced effect
on arrhythmic risk among patients with LBBB at enroll-
ment; 3) despite the beneficial effects of CRT-D on the risk
of a first VTE in LBBB patients, once a patient experiences
an arrhythmic event with the device, the effects of this
therapy on subsequent VTEs are neutral compared with
ICD alone; 4) patients with a non-LBBB morphology
before device implantation experienced an increased risk of
subsequent VTEs with CRT-D; and 5) the occurrence of
recurrent VTEs increases the subsequent risk of death or
heart failure exacerbations.
CRT-D reduces the risk of heart failure exacerbations for
patients at both early and late stages of congestive heart
failure (6,12–14). However, mounting evidence suggests
that the benefit derived from CRT-D varies significantly by
baseline conduction disturbances. The risks of initial heart
failure and initial ventricular arrhythmia were reduced by
CRT-D to a greater extent in patients with LBBB than in
those without LBBB (8,12,15–19). Patients with LBBB
experience greater reverse remodeling than those without
due to correction of greater underlying mechanical dyssyn-
chrony (20–24), and greater reverse remodeling predicts
greater reductions in the risk of a heart failure exacerbation
(25). We recently showed that the reduction in the risk of
ventricular tachyarrhythmic events in MADIT-CRT is
related to the degree of echocardiographic response to the
device (26). Furthermore, in the present study, we show that
the frequency of echocardiographic nonresponse to CRT
was 2-fold higher among non-LBBB patients compared
with LBBB patients and that echocardiographic response to
CRT-D was related to the risk of subsequent VTEs. Thus,
the present findings among non-LBBB patients regarding
ology*
By QRS Morphology
Patients Non-LBBB Patients
p Value for difference‡) p Value HR (95% CI) p Value
7) 0.001 1.05 (0.71–1.54) 0.82 0.02
0) 0.95 3.62 (1.59–8.26) 0.002 0.009
no active device, having limited data, are omitted here. †The endpoint of a first VTE was assessed
bsequent VTEs was assessed in the 310 patients with a first VTE (451 events) using Anderson-Gill
icular end-diastolic volume 240, sex, etiology of heart failure (ischemic or nonischemic), history
nt VTE model, time to first VTE was estimated and found not to be a significant predictor; similar
additional covariate. ‡No other statistically significant interactions in the models for VTEs were
tricular tachyarrhythmic event; other abbreviations as in Table 1.ent
orph
LBBB
5% CI
44–0.7
61–1.6
ods with
int of su
ft ventr
bseque
e as anthe lack of CRT reduction in the risk of a first VTE and
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CRT-D and Recurrent Ventricular Tachyarrhythmias October 30, 2012:1809–16increased risk of subsequent VTEs may be related to the
higher frequency of nonresponders in this patient subset.
Lending biological plausibility to this explanation is evi-
dence that reverse remodeling involves the restoration of
myocardial ion channel homeostasis (27), dysregulation of
which is likely involved in the pathogenesis of arrhythmias
in the setting of heart failure (28–30). In addition, a
potential mechanism for the proarrhythmic role of CRT-D in
non-LBBB patients is the reversal of left ventricular activation
and increased transmural dispersion of repolarization with
epicardial pacing, thus allowing for the development of early
after depolarizations and re-entrant circuits (31,32).
Other factors beyond mechanical dyssynchrony may also
contribute to the differential response to CRT-D illustrated
in this study. For example, the non-LBBB group has a
greater percentage of male patients and ischemic etiology,
both of which have been shown to predict less response to
CRT, although these factors were adjusted for in multivar-
iate analysis (33,34). In addition, data from the InSync
Italian ICD Registry also suggest that VTEs differ in rate
and frequency of self-termination between ischemic and
nonischemic patients (35). Thus, it is possible that CRT-D
Multivariate Analysis: Impact of Time-DependentVTEs on th Occurrence of a First H art FailureEvent o D ath in the Total Study Population
Table 3
Multivariat An lysi : Impac f Time-Dependent
VTEs on the Occurrence of a First Heart Failure
Event or Death in the Total Study Population
Risk Factor HR 95% CI p Value
First VTE vs. no VTE 1.33 0.90–1.96 0.15
Second VTE vs. no VTE 2.44 1.23–4.82 0.01
Third VTE vs. no VTE 3.26 1.79–5.93 0.001
Adjusted for 65 years of age and older at enrollment, assigned treatment at randomization,
diabetes mellitus, heart rate 80, QRS duration 150 ms, ejection fraction 25%, left atrial
volume (treated as a continuous variable), estimated glomerular filtration rate 60; results were
similar in LBBB and non-LBBB patients (all p values for VTE-by-QRS morphology interactions
0.20).
Abbreviations as in Tables 1 and 2.
Figure 3 Percentage of Echocardiographic Nonresponders
to CRT-D at 1 Year of Follow-Up by QRS Morphology
Fractions listed above columns represent the number of nonresponders among
CRT-D patients with and without left bundle branch block, respectively. Echocar-
diographic nonresponse was defined as a 25% reduction in left ventricular
end-systolic volume (LVESV) at 12 months of follow-up, corresponding to less
than the first quartile of percentage of reduction in LVESV. CRT-D  cardiac
resynchronization therapy with a defibrillator.Figure 2
Rate of Second VTE or Death Following
a First Event by Treatment Arm in the Total
Population and Stratified by Baseline LBBB Status
Cumulative probability of a second ventricular tachyarrhythmic event (VTE)
(180 beats/min) or death after the occurrence of a first event in the total
study population (A); study patients with LBBB (B); and study patients without
LBBB (C). Survival curves were limited to time after the occurrence of a first
VTE, with censoring at any device change or explantation. LBBB  left bundle
branch block; abbreviations as in Figure 1.
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October 30, 2012:1809–16 CRT-D and Recurrent Ventricular Tachyarrhythmiasis less effective in preventing certain types of VTEs that are
more common in non-LBBB patients.
This study provides the first evidence that CRT-D does
not reduce the risk of subsequent VTEs in LBBB patients
and appears to be deleterious in patients with other con-
duction disturbances. Progression of patients’ myocardial
disease with further electrical and mechanical changes may
have also contributed to subsequent VTEs. It appears that
this progression is also accompanied by a higher incidence
of heart failure events or death, as shown by our data here.
This lends support for close clinical follow-up of patients
with recurrent VTEs and may call for more aggressive
medical therapy and/or ablation.
Study limitations. The MADIT-CRT was initially de-
signed to identify a treatment effect of CRT-D versus ICD
in terms of first heart failure event or death. As such, this
study may not be adequately powered to detect potential
reductions in the risk of subsequent VTEs in patients with
LBBB. Furthermore, adjustment for any imbalances be-
tween LBBB and non-LBBB groups was accomplished
through the use of covariates in a multivariate model rather
than through randomization.
The primary outcome of the present study included the
occurrence of appropriate ICD therapies (both ATPs and
shocks) delivered for fast VTEs. Thus, endpoint events may
have included therapies delivered for nonlife-threatening
events such as nonsustained VTEs. These events, however,
occurred only in 36 study patients.
Finally, the follow-up duration may have been insufficient
to capture a benefit several years after device implantation.
Conclusions
Although CRT-D does reduce the risk of a first VTE in
LBBB patients, it does not reduce the risk of subsequent
recurrent VTEs. In addition, CRT-D may increase the risk
of subsequent VTEs in patients without LBBB. Data here
demonstrate that baseline QRS morphology may predict a
patient’s risk of future VTEs after implantation of CRT-D.
Our results also suggest that recurrent VTEs have prognostic
implications for heart failure patients, increasing the risk of
subsequent heart failure or death. These findings demonstrate
Multivariate Analysis: Impact ofNonresponder Statu at 12 M nths ofF l ow-Up on the Occurrence of Recurrent VTEs
Table 4
Multivariate Analysis: Impact of
Nonresponder Status at 12 Months of
Follow-Up on the Occurrence of Recurrent VTEs
Treatment Effect HR 95% CI p Value
CRT-D responder* vs. ICD 0.54 0.42–0.68 0.001
CRT-D nonresponder† vs. ICD 1.45 1.17–1.80 0.001
Follow-up for the occurrence of recurrent VTEs was started after the 12-month echocardiographic
assessment. The endpoint of recurrent VTEs (1 event) was assessed using Anderson-Gill
regression modeling. All findings are further adjusted for age 65 years and older at enrollment, left
ventricular end-diastolic volume 240, sex, etiology of heart failure (ischemic or nonischemic),
history of myocardial infarction, and history of a ventricular tachyarrhythmia before enrollment.
*An echocardiographic response to CRT-D was defined as 25% reduction in left ventricular
end-systolic volumes (first quartile) at 1 year of follow-up.
Abbreviations as in Tables 1 and 2.the importance of identifying effective interventions to reducethe risk of subsequent arrhythmic events among patients who
experience a first VTE after device implantation.
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